Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Accessible Chromatin
12%
Carbohydrate Antigen 125 (CA125)
37%
Cell Surface Display
12%
Chemoresistance
25%
Chemotherapy
15%
Chromatin Accessibility
12%
Chromatin Landscape
37%
Clinical Outcomes
15%
COVID-19
37%
Diagnostic Accuracy
12%
DNAM-1
37%
E2F2
12%
Elective Surgery
37%
Gene Regulatory Landscape
12%
High-grade Serous Ovarian Cancer (HGSOC)
37%
HNF4G
12%
Human Epididymis Protein 4
37%
Low Risk
28%
Lymphoid Cells
12%
Major Surgery
28%
Minor Surgery
28%
Myeloid Cells
12%
Nasopharyngeal Swab Testing
37%
Natural Killer Cells
37%
Neoadjuvant Chemotherapy
12%
NK Cell-mediated Killing
37%
NR2F6
12%
Nuclear Receptor
12%
Ovarian Cancer
100%
Ovarian Cancer Cells
12%
Ovarian Metastasis
37%
Post-chemotherapy
37%
Postoperative Pulmonary Complications
37%
Preoperative Testing
18%
Primary Care
31%
Primary Care Population
37%
Proliferative Activity
12%
Pulmonary Complications
28%
Residual Tumor Cells
37%
Risk Areas
37%
Risk of Ovarian Malignancy Algorithm
25%
RORĪ±
12%
SARS-CoV-2 Infection
18%
SARS-CoV-2 Pandemic
37%
Single-cell Chromatin Accessibility
12%
Stress-responsive Genes
12%
Swab Test
37%
TP63
12%
Transcription Factor Binding Sites
12%
Tumor
28%
Medicine and Dentistry
CA-125
37%
Cancer
27%
Cancer Diagnosis
6%
Cancer Surgery
5%
Cohort Analysis
5%
COVID-19
5%
Diagnostic Accuracy
12%
Diseases
5%
Elective Surgery
37%
Epididymis
37%
General Practitioner
6%
Infection
10%
Major Surgery
16%
Malignant Neoplasm
11%
Metastatic Carcinoma
5%
Minor Surgery
16%
Nasopharyngeal Swab
37%
Natural Killer Cell
37%
Neoplasm
10%
Observational Study
6%
Odds Ratio
5%
Ovarian Cancer
74%
Pandemic
37%
Preoperative Testing
10%
Primary Health Care
37%
Primary Tumor
8%
Severe Acute Respiratory Syndrome Coronavirus 2
37%
Tumor Marker
6%
